Skip to main content
. 2021 Mar 18;106(9):2364–2373. doi: 10.3324/haematol.2020.272500

Figure 2.

Figure 2.

Response to acalabrutinib. Patients who discontinued study treatment before evaluation for response (n=6) or who were not available for response assessment (n=2) were classified as not evaluable. CR: complete remission; Cri: CR with incomplete bone marrow recovery; ORR: overall response rate; PD: progressive disease; PR: partial remission; PRL: partial remission with lymphocytosis; SD: stable disease.